miR‑224/miR‑141 ratio as a novel diagnostic biomarker in renal cell carcinoma

作者：Xuanyu Chen, Ning Lou, Anming Ruan, Bin Qiu, Yunqin Yan, Xuegang Wang, Quansheng Du, Hailong Ruan, Weiwei Han, Haibin Wei, Hongmei Yang, Xiaoping Zhang · 发表于：Oncology Letters · 年份：2018 · DOI：10.3892/ol.2018.8874 · 被引用次数：22 · 研究领域：MicroRNA in disease regulation、Circular RNAs in diseases、Cancer-related molecular mechanisms research

Biomarkers to guide the clinical treatment of patients with renal cell carcinoma (RCC) are not yet routinely available. MicroRNAs (miRNAs) have been demonstrated to serve as biomarkers for a number of types of cancer. Based on a previous study by this group, we hypothesize that several highly differentially expressed miRNAs may serve as tissue and plasma biomarkers in patients with RCC. The expression levels of miR‑210, miR‑224 and miR‑141 were analyzed in tissue samples from the same cohort of 78 patients with RCC, in paired pre‑ and post‑operative plasma samples from 66 patients with clear cell RCC (ccRCC) and in 67 healthy controls by reverse transcription‑quantitative polymerase chain reaction. Receiver operating characteristic (ROC) was used to evaluate the diagnostic accuracy associated with the expression of miR‑210, miR‑224 and miR‑141. ROC curves revealed that the diagnostic accuracy (area under the curve) of tissue miR‑210, miR‑224, the ratio of miR‑210/miR‑141 (miR210/141), miR‑224/miR‑141 (miR224/141) and miR‑210x miR‑224/miR‑141 (miR210x224/141) in ccRCC was 0.8329, 0.8511, 0.9412, 0.9898 and 0.9771, respectively. Notably, miR224/141 demonstrated the highest accuracy among these miRNAs for discriminating ccRCC tissues from normal tissues, with a sensitivity of 97.06% and a specificity of 98.53%. The expression levels of plasma miR‑210 and miR‑224 were significantly increased in patients compared with healthy control patients, and were reduced postoperatively (P<0...